First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: CellaVision AB (publ): the story is balanced — New OEM partnership announcements with major hematology analyzer manufacturers (Sysmex, Beckman Coulter, Horiba…
growth - The 68.5% gross margin, 27% ROA, and 30.2% FCF yield attract quality-focused growth investors seeking profitable…
Rising interest rates create modest headwinds through two channels: (1) hospital systems face higher borrowing costs for capital equipment…
Watch on earnings: US hospital capital equipment spending trends (AHA annual survey data, quarterly earnings from Becton Dickinson, Danaher), Global hematology analyzer unit shipment volumes from OEM partners (Sysmex, Beckman Coulter quarterly reports), Medicare Clinical Laboratory Fee Schedule reimbursement rate changes for CBC with differential (CPT 85025, 85027).
One Sentence Summary:
CellaVision AB (publ): the story is balanced — new oem partnership announcements with major hematology analyzer manufacturers (sysmex, beckman coulter, horiba, mindray).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.